• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Julian Orlando Carlson 1997 A Trust claimed ownership of 62,079 shares (SEC Form 3)

    11/1/24 4:05:17 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Julian Orlando Carlson 1997 A Trust

    (Last) (First) (Middle)
    2100 MCKINNEY AVE
    STE 1900

    (Street)
    DALLAS TX 75201

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/23/2024
    3. Issuer Name and Ticker or Trading Symbol
    SWK Holdings Corp [ SWKH ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    See Remarks
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.001 per share the "Common Stock" 62,078.96 D(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares of Common Stock to which this relates are held directly by Julian Orlando Carlson 1997 A Trust.
    Remarks:
    Julian Orlando Carlson 1997 A Trust is an affiliated person of an investment adviser.
    Julian Orlando Carlson 1997 A Trust, By: /s/ Keith T. Anderson, Title: Trustee 10/25/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SWKH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on SWK Holdings with a new price target

      Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      12/28/22 9:18:49 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Lake Street initiated coverage on SWK Holdings with a new price target

      Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      4/18/22 8:44:23 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    SEC Filings

    See more
    • SWK Holdings Corporation filed SEC Form 8-K: Other Events

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/19/25 8:47:29 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:23:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:22:48 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Financials

    Live finance-specific insights

    See more
    • SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

      Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

      11/14/24 4:15:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

      10/17/24 4:15:00 PM ET
      $BTCY
      $DERM
      $ELUT
      $ETON
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT Staggs Joe David Jr exercised 33,750 shares at a strike of $11.22 and covered exercise/tax liability with 25,857 shares, increasing direct ownership by 7% to 123,766 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      4/17/25 4:34:14 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • PRESIDENT Staggs Joe David Jr was granted 36,700 shares, increasing direct ownership by 46% to 115,873 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:55 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Chief Financial Officer Rice Adam was granted 9,175 shares, increasing direct ownership by 151% to 15,247 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImpediMed Secures $15m Growth Capital Funding

      New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

      2/7/25 11:00:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.OriginationsIn November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share.In December, SWK closed an $8.0M senior secured term loan with Triple

      1/6/25 7:35:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Appoints Chief Financial Officer

      Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

      7/8/24 5:00:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Stanley Black & Decker Appoints Chris Nelson Chief Operating Officer and Executive Vice President and President of Tools & Outdoor

      NEW BRITAIN, Conn., May 2, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK) today announced the appointment of Chris Nelson as Chief Operating Officer of the company, and Executive Vice President and President of Tools & Outdoor, effective June 14, 2023. Nelson joins Stanley Black & Decker from Carrier Corporation and brings more than 25 years of leadership experience in general management, product development and innovation, and growth transformation. Nelson will report to Donald Allan Jr., President and CEO of Stanley Black & Decker. He will assume the role of President, Tools & Outdoor, from current Acting Co-Presidents Robert Raff and John Wyatt. Raff will continue to serve as Chie

      5/2/23 4:36:00 PM ET
      $SWK
      $SWKH
      Industrial Machinery/Components
      Consumer Discretionary
      Diversified Financial Services
      Finance

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      11/14/24 11:49:47 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

      SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

      10/25/24 4:05:56 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      2/14/24 2:14:12 PM ET
      $SWKH
      Diversified Financial Services
      Finance